Table 3 Baseline characteristics of patients included for Molecular-Based Score.

From: Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome

Characteristics

All patients

Molecular-Based Score

 

Favorable risk

Intermediate risk

Adverse risk

 

No

%

Median (range)

No

%

Median (range)

No

%

Median (range)

No

%

Median (range)

P value

N

159

100

 

28

17.6

 

60

37.8

 

71

44,6

  

Gender

            

0.08

Female

57

35.8

 

15

46.4

 

21

35

 

21

30

  

Male

102

64.2

 

13

53.6

 

39

65

 

50

70

  

Age, years

  

67 (19—87)

  

63 (32—82)

  

67 (19–87)

  

67 (33–87)

0.439

Bone marrow blasts, %

  

4 (0—63)

  

2.5 (0–14)

  

3 (0–63)

  

8.5 (0–46)

 < 0.001

Hemoglobin, g/dL

  

9.5 (4.5–14.6)

  

10 (6.9–11.9)

  

9.45 (5.4–14.6)

  

9.8 (4.5–14.4)

0.952

Absolute neutrophil count, × 103/µL

  

1.8 (0.08–15.2)

  

2.5 (0.91–5.36)

  

2.3 (0.38–6.4)

  

1.3 (0.08–15.2)

0.003

Platelets, × 103/µL

  

152 (10–1042)

  

250 (38–787)

  

157 (16–604)

  

109 (10–1042)

0.007

Transfusion dependency

            

0.627

Yes

58

44.3

 

9

57.1

 

27

55.1

 

30

52.7

  

No

73

55.7

 

16

32.1

 

22

44.9

 

27

47.3

  

IPSS-R

            

 < 0.001

Very-low

27

17.0

 

8

28.6

 

14

23.3

 

5

7.1

  

Low

53

33.3

 

12

42.9

 

26

43.3

 

15

21.4

  

Intermediate

44

27.7

 

5

17.9

 

15

25

 

24

33.8

  

High

23

14.5

 

3

10.7

 

1

1.7

 

19

26.8

  

Very-high

12

7.5

 

0

0

 

4

6.7

 

8

11.3

  

WHO 2008 category

            

 < 0.001

RA

13

8.2

 

1

3.6

 

9

15

 

3

4.2

  

RCMD

27

17.0

 

1

3.6

 

16

26.7

 

10

14.1

  

RCMD-RS

22

13.8

 

7

25

 

10

16.7

 

5

7

  

RARS

14

8.8

 

8

28.6

 

4

6.7

 

2

2.9

  

RARS-T

6

3.8

 

4

14.3

 

2

3.3

 

0

0

  

MDS with 5q-

6

3.8

 

2

7.1

 

4

6.7

 

0

0

  

RAEB

28

17.6

 

1

3.6

 

9

15

 

18

25.3

  

RAEB-2

28

17.6

 

4

14.3

 

3

5

 

21

29.6

  

AML-MDS

7

4.4

 

0

0

 

1

1.7

 

6

8.4

  

NA

8

5.0

 

0

0

 

2

3.3

 

6

8.4

  

Mutations

             

SF3B1

37

29.8

 

14

50

 

15

31.9

 

8

14.8

 

 < 0.001

TET2

33

20.8

 

5

21.7

 

14

29.8

 

14

25.6

 

0.765

ASXL1

21

13.2

 

2

8.7

 

6

12.8

 

13

24.1

 

0.161

SRSF2

16

10.1

 

1

4.3

 

6

12.7

 

9

16.7

 

0.336

DNMT3A

13

8.2

 

3

13

 

7

14.9

 

3

5.5

 

0.282

RUNX1

8

6.5

 

0

0

 

1

2.1

 

7

12.9

 

0.03

U2AF1

8

6.5

 

1

4.3

 

1

2.1

 

6

11.2

 

0.168

  1. IPSS-R: Revised International Prognostic Score System; RA: refractory anemia; RCMD: refractory cytopenia with multilineage dysplasia; RCMD-RS: refractory cytopenia with multilineage dysplasia with ring sideroblasts; RARS: refractory anemia with ring sideroblasts; RARS-T: refractory anemia with ring sideroblasts and thrombocytosis; RAEB: refractory anemia with excess blasts. AML-MDS: acute myeloid leukemia with myelodysplastic alterations; NA: Not available.
Back to article page